TL;DR
The White House said Tuesday it had withdrawn Heidi Overton’s nomination to lead the FDA, ahead of a Senate committee vote scheduled for Wednesday. Overton faced bipartisan concerns about her scientific independence and vaccine positions, while the agency remains under acting leadership.
The White House said Tuesday it had withdrawn Heidi Overton’s nomination to lead the Food and Drug Administration, as doubts grew that she could win Senate confirmation. Her withdrawal leaves the FDA under acting commissioner Kyle Diamantas while the agency faces scrutiny over recent staff losses and internal disputes.
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Overton, a physician and White House domestic policy adviser, was nominated in August. The Senate Health, Education, Labor, and Pensions Committee had been scheduled to consider her nomination Wednesday. To advance through the committee, she needed support from all 12 Republicans; Democrats hold 11 seats. Without a committee majority, her prospects for confirmation by the full Senate were slim.
Sen. Bill Cassidy, a Louisiana Republican who chairs the committee, said Tuesday he remained undecided. He had questioned Overton at a September hearing about whether she would act independently of President Donald Trump and Health Secretary Robert F. Kennedy Jr. Cassidy had also called her support for Trump’s plan to split up combination vaccines, including the measles, mumps, and rubella vaccine, “almost disqualifying.”
Overton’s nomination drew criticism from more than one political direction. Some influential figures in the Make America Healthy Again movement accused White House officials, including Overton, of obstructing Kennedy’s health priorities. Calley Means, a movement supporter, said on the Joe Rogan podcast earlier this month that White House aides had helped advance a Supreme Court decision blocking thousands of lawsuits over the weedkiller glyphosate, and alleged that industry lobbyists influenced that and other decisions. Those statements are Means’ claims, not independently established findings in the source report.
An FDA Leadership Post Stays Unsettled
The withdrawal means the FDA will continue without a Senate-confirmed commissioner while political disagreements over the agency’s direction remain unresolved. The commissioner leads a regulator responsible for oversight of food, medicines, vaccines, and other products, making the role central to decisions with broad public-health and industry consequences.
The change also underscores the difficulty the administration has faced in securing Senate backing for health nominees. The report describes a year of scientific disputes and leadership changes at the FDA under former commissioner Marty Makary, as well as low morale and internal dysfunction. It says the agency has lost about 20% of its employees through layoffs, buyouts, retirements, or resignations since Trump took office. The report does not specify a measurement date or provide a separate baseline for that figure.
With the agency led on an acting basis, questions about continuity and who will set its longer-term priorities remain relevant to patients, health professionals, regulated companies, and FDA staff. The withdrawal itself does not establish that any particular policy or regulatory decision will change.
Products Worth Considering

Bose SoundTouch 30 Wireless Speaker, Black

Apple AirPods Pro 3 Wireless Earbuds with Active Noise Cancellation

Samsung 27-Inch Odyssey G5 QHD Gaming Monitor (G50F)
As an affiliate, we earn on qualifying purchases.
A Nomination Tested by Vaccine Disputes
Overton’s August nomination was described as an effort to bring a stabilizing Trump loyalist to the FDA after a turbulent period under Makary. Her background included work for Trump and conservative groups aligned with his agenda. In the Senate, however, the debate focused in part on whether she would maintain scientific independence when her views or decisions differed from those of the president or Kennedy.
The committee vote was especially consequential because Republicans were seeking to confirm the administration’s pending nominees before control of the Senate shifted to Democrats in January, according to the report. Cassidy had previously pressed health nominees, including Kennedy, for commitments on vaccine standards and threatened to withhold support, but had ultimately voted for each nominee who came before his committee. Cassidy lost a June primary in his bid for a third Senate term, leaving him with only weeks in office at the time of the nomination dispute.
Overton was not the first health nominee the White House had pulled. The administration replaced its first CDC nominee, David Weldon, after questions about his Republican support. It also withdrew two surgeon general nominees, including Casey Means, after resistance from Senate Republicans.
“He said Tuesday he remained undecided about Overton.”
— Sen. Bill Cassidy
Who Will Lead the FDA Permanently?
The White House’s announcement, as described in the report, does not say who will be nominated next or when a replacement might be named. It is also unclear how long Kyle Diamantas will remain acting commissioner, or whether the administration will seek a nominee with a different profile.
The precise reasons for the withdrawal were not fully detailed beyond mounting concerns about Senate votes. The report points to Cassidy’s undecided position and the committee’s narrow vote math, but it does not provide a formal White House explanation of the decision. Nor does it establish whether Overton’s positions on vaccines or criticism from MAHA figures individually determined the outcome.
A New Nominee or Continued Acting Leadership
The Senate committee vote scheduled for Wednesday will no longer decide Overton’s nomination following the White House withdrawal. The next significant development will be whether the administration names another FDA commissioner nominee or leaves Diamantas in the acting role while it considers its options.
Any new nominee would face Senate scrutiny, including questions about scientific independence, vaccine policy, and the agency’s management. The report does not give a timeline for a replacement nomination or say what steps the White House plans to take next.
Key Questions
Why was Heidi Overton’s nomination withdrawn?
The White House said Tuesday it had withdrawn the nomination. The report links the decision to growing signs that Overton lacked enough Senate support, including uncertainty from committee chair Bill Cassidy, but does not provide a fuller official explanation.
Who is leading the FDA now?
Kyle Diamantas is serving as acting FDA commissioner, according to the report. The White House has not announced in the source material who will be nominated for the permanent role.
What concerns did senators raise about Overton?
Senators questioned whether she would act independently of President Trump and Health Secretary Robert F. Kennedy Jr. Cassidy also criticized her support for a plan to separate combination vaccines, including the measles, mumps, and rubella vaccine.
Was Overton’s nomination scheduled for a Senate vote?
A Senate health committee vote was scheduled for Wednesday, November 18, 2026. The White House withdrew the nomination the previous day, so the planned committee vote would no longer determine her confirmation.
Source: medpagetoday.com
